COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Colorado Based Ascent Classical Academy Charter Schools, Inc. Successfully Sells $77.5 Million in Bonds to Support Campus Acquisitions and Expansion
Ascent Classical Academy Charter Schools, Inc. successfully sells $77,515,000 in bonds to enhance educational opportunities in Colorado. Investors show confidence in ACACS's financial stability and growth potential -
-
COMMUNIQUÉ DE PRESSE
Valkyrie Announces New AI Company, Andromeda, Raises $4.5M in Austin’s Largest Pre-Seed Round
Valkyrie launches Andromeda, a decision intelligence platform for national security and high-accountability enterprises, powered by transformers and knowledge graphs. The platform offers unbiased insights for successful mission outcomes -
-
COMMUNIQUÉ DE PRESSE
PureVPN Launches PureVPN for Teams to Address Security Needs of Small Businesses
PureVPN introduces PureVPN for Teams, a cybersecurity solution for small businesses, offering end-to-end security and efficient teamwork. Enhancing data safety, simplified admin dashboard, improved collaboration, compliance assurance -
COMMUNIQUÉ DE PRESSE
HiiiWAV Fest Overcomes City Budget Deficit to Launch Oakland’s 1st Music and Tech Festival June 8th
HiiiWAV presents HiiiWAV Fest, combining AI & VR tech with Black music in Oakland on June 8th. Event saved by sponsors after city grant delay. Join to support at hiiiwav.org/donate -
COMMUNIQUÉ DE PRESSE
New York Sephardic Jewish Film Festival Honors Reymonde Amsellem, Alexandre Arcady, Stella Levi, & John Turturro; Features Enrico Macias Opening Night Performance
The American Sephardi Federation's 26th New York Sephardic Film Festival opens on June 2 at the Center for Jewish History. Featuring honorees like Alexandre Arcady, Stella Levi, and John Turturro, the festival showcases Sephardic culture through film premieres and special performances -
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar announces expansion of out-licensing agreement with Magdalena Biosciences for Botanical Drug Candidate targeting schizophrenia market. Company to present at Lytham Partners Spring 2024 Investor Conference
